ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements
Aakaar Medical Technologies provided an operational update for Q1 FY2026-27, detailing expansion in its clinic network, distributor count, and overall sales force effectiveness.
Aakaar Medical Technologies addressed an NSE notice regarding Regulation 44(3) non-compliance, stating the lapse was inadvertent and that corrective measures have been implemented.
Aakaar Medical Technologies submitted a share‑capital audit reconciliation reporting issued capital of ₹14.17 Crore. The filing satisfies SEBI (Depositories and Participants) Regulation 76 requirements.
Aakaar Medical Technologies appointed NAM & ASSOCIATES as Secretarial Auditor for a five-year term. The firm brings extensive experience in corporate and foreign exchange laws.
Aakaar Medical Technologies held its 13th AGM on June 30, 2026. Key outcomes include financial approval and increasing authorized share capital.
Aakaar Medical Technologies reported FY26 revenue of INR 67 Cr (up 8.6%) and PAT of INR 6.63 Cr (up 10%). The company is shifting towards an asset-light DODO clinic model via its Xelix platform.
Aakaar Medical Technologies released its FY 2025-26 annual report and scheduled its 13th AGM for June 30, 2026. The report highlights ten consecutive years of PAT positivity.
Aakaar Medical Technologies reported zero deviation in utilizing its ₹27 Crore IPO proceeds. The filing confirms funds were deployed according to the stated prospectus objects.
Aakaar Medical Technologies reported FY26 revenue of ₹66.96 Crore and net profit of ₹6.64 Crore. The board also approved re-appointing Mr. Dilip Ramesh Meswani as Director.
Aakaar Medical Technologies approved a new 2026 Employee Stock Option Plan and increased its authorized share capital. These measures aim to enhance employee retention and capital flexibility.
Aakaar Medical Technologies will hold its 13th AGM on June 30, 2026. The record date for determining shareholder eligibility is fixed for May 29, 2026.
Aakaar Medical Technologies reported strong FY26 recovery with ₹66.9cr revenue and record H2 profitability driven by high-margin product launches and improved debtor discipline.
Aakaar Medical Technologies scheduled a board meeting for May 22, 2026. Directors will discuss ESOP implementation and increasing the company's authorized share capital.
Aakaar Medical Technologies Ltd reported revenue from operations of ₹41.6 Cr (+22.7% YoY) and net profit of ₹7.4 Cr (+32.1% YoY) for H2 FY26.
Aakaar Medical Technologies reported H2FY26 revenue of ₹41.6 Cr and PAT of ₹7.4 Cr, successfully pivoting to higher-margin owned brands and cash-first billing.
Aakaar Medical Technologies updated its Code of Fair Disclosure for Unpublished Price Sensitive Information. This aligns internal policies with SEBI Insider Trading Regulations for better governance.
Aakaar Medical Technologies submitted its annual Structured Digital Database compliance certificate for FY2026. The filing confirms regulatory adherence despite a brief, resolved technical issue.